STOCK TITAN

Citius Pharmaceuticals to Present at the LD Micro Invitational XIV Investor Conference

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags
conferences
Argus Session date unavailable
-1.73% session move Open Argus
Details

News Market Reaction – CTXR

The recorded move for CTXR in the trading session of this news was -1.73%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

CRANFORD, N.J., April 4, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that Chairman and CEO Leonard Mazur will present at the 14th Annual LD Micro Invitational investor conference being held April 8-9, 2024, in New York City.

Conference Details:

Presentation:

3:30pm ET on April 9, 2024

Format:

In-person and virtual

Location:

Sofitel New York, New York City

Conference attendance:

Register on the conference website

Livestream:

Register here

1x1 meetings:

Upon request by registered investors

About Citius Pharmaceuticals, Inc.

Citius Pharma is a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. The Company's diversified pipeline includes two late-stage product candidates. At the end of 2023, Citius completed enrollment in a Phase 3 Pivotal superiority trial of Mino-Lok®, an antibiotic lock solution to salvage catheters in patients with catheter-related bloodstream infections. A Biologics License Application for LYMPHIR™, a novel IL-2R immunotherapy for an initial indication in the treatment of cutaneous T-cell lymphoma, is currently under review by the FDA with August 13, 2024 assigned as the PDUFA target action date. Citius previously announced plans to form Citius Oncology, a standalone publicly traded company with LYMPHIR as its primary asset. LYMPHIR received orphan drug designation by the FDA for the treatment of CTCL and PTCL. In addition, Citius completed enrollment in its Phase 2b trial of CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. For more information, please visit www.citiuspharma.com.

Investor Contact:

Ilanit Allen
ir@citiuspharma.com
908-967-6677 x113

Citius Pharmaceuticals, a late-stage biopharmaceutical company (PRNewsfoto/Citius Pharmaceuticals, Inc.)

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/citius-pharmaceuticals-to-present-at-the-ld-micro-invitational-xiv-investor-conference-302108125.html

SOURCE Citius Pharmaceuticals, Inc.

Keep reading